No profile data available.
Mesoblast Limited (MESO) is a healthcare company in the organ transfer treatment drugs industry, based in Melbourne, Australia, with about 108 full-time employees.
It reported revenue of $120.25 million for fiscal year 2026, up 599.2% from fiscal year 2025, and net income of -$57.50 million. Its market capitalization was $1.86 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2026; market data as of October 9, 2026.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Mesoblast reported $120.25 million in revenue for fiscal year 2026, up 599.2% from $17.20 million in fiscal year 2025.
$1.86 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (organ transfer treatment drugs) include Syndax Pharmaceuticals, Inc. (SNDX), Omeros Corporation (OMER), Eledon Pharmaceuticals, Inc. (ELDN), Equillium, Inc. (EQ).